Searched over 200M research papers for "pcos ivf"
10 papers analyzed
These studies suggest that IVF for PCOS patients can be optimized with careful low dose stimulation, GnRH agonist trigger, embryo freezing, and segmentation of the cycle, while in vitro maturation (IVM) may offer a safer and effective alternative, and weight loss, myoinositol therapy, and elective embryo cryopreservation can improve outcomes and reduce risks.
20 papers analyzed
Polycystic ovarian syndrome (PCOS) is a prevalent endocrine disorder affecting women of reproductive age, with a prevalence ranging from 8.7% to 17% depending on diagnostic criteria. Women with PCOS often face subfertility, necessitating the use of assisted reproductive technologies (ART) such as in vitro fertilization (IVF). However, IVF in PCOS patients presents unique challenges, including an exaggerated ovarian response, poor egg quality, and increased risk of ovarian hyperstimulation syndrome (OHSS) .
Careful planning of ovarian stimulation is crucial for PCOS patients undergoing IVF. Low-dose stimulation protocols, considering anti-Müllerian hormone (AMH) levels and antral follicle count, are recommended to achieve optimal responses and minimize risks. The use of gonadotrophin-releasing hormone (GnRH) antagonists and agonists can help manage the ovarian response and reduce the incidence of OHSS .
In vitro maturation (IVM) of oocytes is a promising alternative for PCOS patients, potentially reducing the risk of OHSS. IVM involves retrieving immature oocytes and maturing them in vitro before fertilization. Studies have shown that IVM can result in higher clinical pregnancy rates and similar live birth rates compared to conventional IVF, with a significantly lower risk of OHSS . However, more high-quality randomized controlled trials are needed to establish definitive practice guidelines.
Meta-analyses comparing conventional IVF outcomes in PCOS and non-PCOS patients reveal mixed results. PCOS patients tend to have a higher number of oocytes retrieved but face challenges such as lower fertilization rates and increased cycle cancellation rates. Despite these challenges, clinical pregnancy and live birth rates per cycle are comparable between PCOS and non-PCOS patients . However, PCOS patients are at higher risk for pregnancy-related complications, including miscarriage, gestational diabetes, and preterm birth.
Weight loss in obese PCOS patients can significantly improve IVF outcomes. Studies indicate that losing more than 5 kg before IVF can enhance ovarian responsiveness, improve embryo quality, and increase clinical pregnancy and live birth rates while reducing miscarriage rates. Weight loss also positively affects hormonal profiles and insulin resistance, contributing to better reproductive outcomes.
Supplementation with myoinositol and folic acid has been shown to improve oocyte quality, fertilization rates, and embryo quality in PCOS patients undergoing IVF. This combination can also reduce the duration of ovarian stimulation and the amount of gonadotropins required, potentially lowering the risk of OHSS.
Elective embryo cryopreservation followed by frozen-thawed embryo transfer (FET) may offer advantages over fresh embryo transfer in PCOS patients. Preliminary data suggest that FET can result in higher clinical pregnancy rates and reduce the risk of pregnancy complications associated with fresh transfers. Ongoing trials aim to provide more robust evidence to support this approach.
IVF in PCOS patients requires tailored approaches to manage the unique challenges posed by the condition. Strategies such as low-dose ovarian stimulation, IVM, weight loss, and myoinositol supplementation can improve outcomes. Additionally, elective embryo cryopreservation followed by FET may offer further benefits. Continued research and well-designed clinical trials are essential to refine these strategies and optimize IVF success rates for PCOS patients.
Most relevant research papers on this topic